Skip to main content
. 2012 Jan 26;33(2):173–181. doi: 10.1007/s10059-012-2240-z

Fig. 1.

Fig. 1.

Rosiglitazone reduces the number of TRAP-positive cells in a dose-dependent manner. Bone marrow cells were exposed to the indicated concentrations of rosiglitazone in the presence of 50 ng/ml M-CSF and 100 ng/ml RANKL. The control and experimental bone marrow cells were subjected to TRAP staining (A), and the numbers of TRAP-positive cells (B) and TRAP-positive MNCs (C) were counted seven days after exposure. *P < 0.05 and ***P < 0.001 vs. the cells containing M-CSF and RANKL.